ANIXA BIOSCIENCES INC Revenue 2010-2022 | ANIX

ANIXA BIOSCIENCES INC revenue from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
ANIXA BIOSCIENCES INC Annual Revenue
(Millions of US $)
2021 $1
2020 $
2019 $0
2018 $1
2017 $0
2016 $0
2015 $9
2014 $4
2013 $0
2012 $1
2011 $1
2010 $1
2009 $1
ANIXA BIOSCIENCES INC Quarterly Revenue
(Millions of US $)
2022-01-31
2021-10-31 $-0
2021-07-31
2021-04-30
2021-01-31 $1
2020-10-31
2020-07-31
2020-04-30
2020-01-31
2019-10-31
2019-07-31
2019-04-30 $0
2019-01-31
2018-10-31 $0
2018-07-31 $0
2018-04-30 $1
2018-01-31
2017-10-31
2017-07-31 $0
2017-04-30
2017-01-31
2016-10-31 $0
2016-07-31 $0
2016-04-30
2016-01-31
2015-10-31
2015-07-31 $0
2015-04-30 $0
2015-01-31 $9
2014-10-31 $1
2014-07-31 $1
2014-04-30 $1
2014-01-31
2013-10-31
2013-07-31
2013-04-30
2013-01-31
2012-10-31 $-0
2012-07-31 $0
2012-04-30 $0
2012-01-31 $0
2011-10-31 $0
2011-07-31 $0
2011-04-30 $0
2011-01-31 $0
2010-10-31 $0
2010-07-31 $0
2010-04-30 $0
2010-01-31 $0
2009-10-31 $0
2009-07-31 $0
2009-04-30 $0
2009-01-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.100B $0.001B
Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00